The writer is a Mumbai-based commentator on the pharma and healthcare sectors
Indian healthcare providers need to get serious about infection control.
Web drug platforms can only be as good as their partner-chemists on the ground.
Changing the FDI policy wont improve the availability of essential drugs.
The ban on a popular diabetes drug only shows poor side-effects monitoring
The Ranbaxy scandal is more damaging to Indian pharmas image than its business prospects